Land: Singapur
Sprache: Englisch
Quelle: HSA (Health Sciences Authority)
Imatinib Mesylate (Form-α) eqv Imatinib
HETERO SINGAPORE PTE. LTD.
L01EA01
TABLET, FILM COATED
Imatinib Mesylate (Form-α) eqv Imatinib 100.00mg
ORAL
Prescription Only
Hetero Labs Limited, Unit-VI
ACTIVE
2021-07-22
IMATINIB TABLETS 100 mg and 400 mg Film-Coated Tablets FORMULATION Imatinib Tablets 100 mg: Each Film-Coated tablet contains 119.50 mg of Imatinib Mesilate equivalent to 100 mg of Imatinib. Imatinib Tablets 400 mg: Each Film-Coated tablet contains 478.00 mg of Imatinib Mesilate equivalent to 400 mg of Imatinib. DESCRIPTION Imatinib is a small molecule kinase inhibitor. Imatinib mesilate film-coated tablets contain imatinib mesilate equivalent to 100 mg or 400 mg of imatinib free base. Imatinib mesilate is designated chemically as 4-[(4-Methyl1-piperazinyl)methyl]- N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]benzamide methanesulfonate. The structural formula is as follows: Imatinib mesilate is a white to off-white to brownish or yellowish tinged crystalline powder. Its molecular formula is C H N O CH SO and its molecular weight is 589.7. Imatinib mesilate is soluble in aqueous buffers ≤ pH 5.5 but is very 29 31 7 4 3 slightly soluble to insoluble in neutral/alkaline aqueous buffers. In non-aqueous solvents, the drug substance is freely soluble to very slightly soluble in dimethyl sulfoxide, methanol and ethanol, but is insoluble in n-octanol, acetone and acetonitrile. THERAPEUTIC INDICATIONS Imatinib is indicated for the · treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) (for paediatric use see section DOSAGE REGIMEN AND ADMINISTRATION). · treatment of adult and paediatric patients with Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy (for paediatric use see section DOSAGE REGIMEN AND ADMINISTRATION). · treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. · treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy. · treatment of adult patients with Kit+ (CD117) unresectable and/or metastatic malignant gastrointestinal stromal tum Lesen Sie das vollständige Dokument